Indian markets saw a dip on Friday, with IT stocks leading the decline. Analysts suggest profit-taking occurred near the 24,150 mark. Despi...

A sector leader is not just the company with the largest market share. Market share matters, but it is a result, not a cause. The cause is ...

Reliance Industries is set to reinvent its oil-to-chemicals business. The company will convert crude oil into advanced materials and green ...

As the bulls attempt another serious comeback, the market again faces a familiar question: Are valuations still too high, or have they reac...

Trent Ltd stock has broken out of a bullish reversal pattern. Experts recommend buying the stock for a target of Rs 3,500 in the next one t...

From a macro perspective, it is clearly a good time to be bullish. But as valuations remain high in parts of the market despite the recent ...

As the market seems to be in comeback mode, it helps to be aware that the best (and probably biggest) wealth creator of the last couple of ...

The conditions that created the worst 18 months for small-caps are starting to ease. The US-Iran war is moving towards settlement. Crude pr...

Zydus Lifesciences' shares dipped 2% after completing the $166.4 million acquisition of US-based Assertio Holdings Inc. The deal, finalized...

Indian drugmaker Biocon aims to be the world's top insulin supplier within five years, capitalising on growing demand as major pharmaceutic...

Indian pharma is shifting from generics to innovation. This transformation, extending to 2035, is creating significant new opportunities. C...

Easing West Asia tensions boost global markets, prompting investors to reassess opportunities. Market veteran Sudip Bandyopadhyay favors ph...

Brokerages remain selective on India's energy sector, favouring companies with strong growth drivers and attractive valuations. Morgan Stan...

Markets rallied sharply as easing US–Iran tensions and softer crude prices boosted sentiment. Sensex and Nifty surged 2%, adding Rs 10 lakh...

Domestic markets recovered modestly on easing oil prices and selective buying in banking and pharma stocks. Analysts have recommended Allie...

Indian pharma stocks are outperforming the market, offering strong returns to investors. This resilience is driven by robust domestic deman...

A promoter entity of Ajanta Pharma sold shares worth over Rs 1,024 crore through a block deal, with Kotak Mahindra Mutual Fund and Aditya B...